‘Experimental design’: these words signal a section of a research paper that many readers might be inclined to scan fleetingly, before moving on to the actual findings. But a study in Nature this week ...
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies. The Food and Drug Administration (FDA), with Imunon Inc., has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback